These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 1321137)

  • 1. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase.
    Rabbani SA; Mazar AP; Bernier SM; Haq M; Bolivar I; Henkin J; Goltzman D
    J Biol Chem; 1992 Jul; 267(20):14151-6. PubMed ID: 1321137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor.
    Ballance DJ; Marshall JM; Cottingham IR; Steven J; Berry SJ; Cederholm-Williams SA; Goodey AR; Courtney M
    Eur J Biochem; 1992 Jul; 207(1):177-83. PubMed ID: 1321039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The kringle stabilizes urokinase binding to the urokinase receptor.
    Bdeir K; Kuo A; Sachais BS; Rux AH; Bdeir Y; Mazar A; Higazi AA; Cines DB
    Blood; 2003 Nov; 102(10):3600-8. PubMed ID: 12881310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains: amino-terminal fragment and kringle domain.
    Kim KS; Hong YK; Lee Y; Shin JY; Chang SI; Chung SI; Joe Y
    Exp Mol Med; 2003 Dec; 35(6):578-85. PubMed ID: 14749538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator.
    Magdolen V; Rettenberger P; Koppitz M; Goretzki L; Kessler H; Weidle UH; König B; Graeff H; Schmitt M; Wilhelm O
    Eur J Biochem; 1996 May; 237(3):743-51. PubMed ID: 8647121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function.
    Fischer K; Lutz V; Wilhelm O; Schmitt M; Graeff H; Heiss P; Nishiguchi T; Harbeck N; Kessler H; Luther T; Magdolen V; Reuning U
    FEBS Lett; 1998 Oct; 438(1-2):101-5. PubMed ID: 9821967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitogenic effects of urokinase on melanoma cells are independent of high affinity binding to the urokinase receptor.
    Koopman JL; Slomp J; de Bart AC; Quax PH; Verheijen JH
    J Biol Chem; 1998 Dec; 273(50):33267-72. PubMed ID: 9837898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding.
    Quax PH; Grimbergen JM; Lansink M; Bakker AH; Blatter MC; Belin D; van Hinsbergh VW; Verheijen JH
    Arterioscler Thromb Vasc Biol; 1998 May; 18(5):693-701. PubMed ID: 9598826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor.
    Cubellis MV; Andreasen P; Ragno P; Mayer M; Danø K; Blasi F
    Proc Natl Acad Sci U S A; 1989 Jul; 86(13):4828-32. PubMed ID: 2544876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The chemotactic action of urokinase on smooth muscle cells is dependent on its kringle domain. Characterization of interactions and contribution to chemotaxis.
    Mukhina S; Stepanova V; Traktouev D; Poliakov A; Beabealashvilly R; Gursky Y; Minashkin M; Shevelev A; Tkachuk V
    J Biol Chem; 2000 Jun; 275(22):16450-8. PubMed ID: 10749881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
    Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
    Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amino-terminal fragment of urokinase-type plasminogen activator inhibits its plasminogen activation.
    Sun Z; Zhang PX; Wang P; Gurewich V; Shen HY; Liu JN
    Thromb Res; 2002 Apr; 106(2):105-11. PubMed ID: 12182908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
    Zhu F; Jia S; Xing G; Gao L; Zhang L; He F
    DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotactic effect of urokinase plasminogen activator: a major role for mechanisms independent of its proteolytic or growth factor domains.
    Poliakov AA; Mukhina SA; Traktouev DO; Bibilashvily RS; Gursky YG; Minashkin MM; Stepanova VV; Tkachuk VA
    J Recept Signal Transduct Res; 1999 Nov; 19(6):939-51. PubMed ID: 10533982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
    Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urokinase plasminogen activator induces smooth muscle cell migration: key role of growth factor-like domain.
    Stepanova V; Bobik A; Bibilashvily R; Belogurov A; Rybalkin I; Domogatsky S; Little PJ; Goncharova E; Tkachuk V
    FEBS Lett; 1997 Sep; 414(2):471-4. PubMed ID: 9315743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor binding and degradation of urokinase-type plasminogen activator by human mesangial cells.
    Nguyen G; Li XM; Peraldi MN; Zacharias U; Hagège J; Rondeau E; Sraer JD
    Kidney Int; 1994 Jul; 46(1):208-15. PubMed ID: 7933839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urokinase plasminogen activator induces human smooth muscle cell migration and proliferation via distinct receptor-dependent and proteolysis-dependent mechanisms.
    Stepanova V; Mukhina S; Köhler E; Resink TJ; Erne P; Tkachuk VA
    Mol Cell Biochem; 1999 May; 195(1-2):199-206. PubMed ID: 10395084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases.
    Appella E; Robinson EA; Ullrich SJ; Stoppelli MP; Corti A; Cassani G; Blasi F
    J Biol Chem; 1987 Apr; 262(10):4437-40. PubMed ID: 3031025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural investigations of recombinant urokinase growth factor-like domain.
    Beloglazova IB; Beabealashvilli RSh; Gursky YG; Bocharov EV; Mineev KS; Parfenova EV; Tkachuk VA
    Biochemistry (Mosc); 2013 May; 78(5):517-30. PubMed ID: 23848154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.